Providers increasingly weigh cost when deciding on cancer drugs

12/14/2012 | Reuters

When making decisions about cancer treatments, health care providers are increasingly taking costs into account, something that is likely to increase under the Affordable Care Act, which features value-focused provisions including measures that tie reimbursements to quality of care. Eighty percent of U.S. health insurers require clear evidence of clinical benefit or cost savings before covering new drugs, according to a survey by PricewaterhouseCoopers.

View Full Article in:


Published in Brief: